Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 11,087 Shares of Stock

Key Points

• CEO Shao-Lee Lin sold 11,087 Cue Biopharma shares at an average price of $27.55, totaling $305,446.85. The sale was intended to cover tax withholding obligations, reducing her stake by 1.57% to 694,908 shares.
• Cue Biopharma shares fell to $18.60, well below their 50-day moving average of $27.73 and 52-week high of $45.50. The company reported a significant quarterly EPS miss, posting a loss of $24.14 versus the $1.69 consensus estimate.
• Analyst sentiment is mixed, with ratings ranging from Strong Buy to Strong Sell and an overall average rating of Hold. The average analyst price target is $83.00, while institutional investors own 35.04% of the stock.

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) CEO Shao-Lee Lin sold 11,087 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total value of $305,446.85. Following the sale, the chief executive officer owned 694,908 shares in the company, valued at approximately $19,144,715.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96.
• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Stock Performance

Cue Biopharma stock traded down $0.97 during midday trading on Wednesday, reaching $18.60. 244,958 shares of the stock were exchanged, compared to its average volume of 475,854. The company's fifty day moving average is $27.73 and its 200-day moving average is $72.25. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. As a group, analysts expect that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

CUE has been the topic of several research analyst reports. Zacks Research upgraded shares of Cue Biopharma to a "hold" rating in a research report on Monday, September 21st. Weiss Ratings lowered shares of Cue Biopharma from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 27th. B. Riley Financial started coverage on shares of Cue Biopharma in a research report on Friday, September 18th. They set a "buy" rating and a $83.00 target price for the company. Finally, Wall Street Zen cut shares of Cue Biopharma from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cue Biopharma currently has an average rating of "Hold" and an average price target of $83.00.

Institutional Investors Weigh In On Cue Biopharma

Several hedge funds have recently added to or reduced their stakes in CUE. Northwestern Mutual Wealth Management Co. bought a new stake in Cue Biopharma in the 2nd quarter worth approximately $83,000. Bank of America Corp DE bought a new position in Cue Biopharma during the second quarter valued at approximately $219,000. Seven Fleet Capital Management LP bought a new position in Cue Biopharma during the second quarter valued at approximately $338,000. Persistent Asset Partners Ltd purchased a new position in shares of Cue Biopharma during the second quarter worth approximately $389,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cue Biopharma during the second quarter worth approximately $722,000. Institutional investors own 35.04% of the company's stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company's approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma's pipeline includes biologic product candidates intended to target cancer-associated antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.